Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 15;28(24):5272-5279.
doi: 10.1158/1078-0432.CCR-22-1183.

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Daniel A Pollyea  1 , Keith W Pratz  2 , Andrew H Wei  3 , Vinod Pullarkat  4 , Brian A Jonas  5 , Christian Recher  6 , Sunil Babu  7 , Andre C Schuh  8 , Monique Dail  9 , Yan Sun  10 , Jalaja Potluri  10 , Brenda Chyla  10 , Courtney D DiNardo  11
Affiliations

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Daniel A Pollyea et al. Clin Cancer Res. .

Abstract

Purpose: To evaluate efficacy and safety of venetoclax + azacitidine in treatment-naïve patients with acute myeloid leukemia harboring poor-risk cytogenetics and TP53mut or TP53wt.

Patients and methods: We analyzed data from a phase III study (NCT02993523) comparing venetoclax (400 mg orally days 1-28) + azacitidine (75 mg/m2 days 1-7) or placebo + azacitidine, and from a phase Ib study (NCT02203773) of venetoclax + azacitidine. Patients were ineligible for intensive therapy. TP53 status was analyzed centrally; cytogenetic studies were performed locally.

Results: Patients (n = 127) with poor-risk cytogenetics receiving venetoclax + azacitidine (TP53wt = 50; TP53mut = 54) were compared with patients with poor-risk cytogenetics (n = 56) receiving azacitidine alone (TP53wt = 22; TP53mut = 18).For poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine versus azacitidine alone resulted in composite remission rates (CRc) of 70% versus 23%, median duration of remission (DoR) of 18.4 versus 8.5 months, and median overall survival (OS) of 23.4 versus 11.3 months, respectively. Outcomes with venetoclax + azacitidine were comparable with similarly treated patients with intermediate-risk cytogenetics and TP53wt.For poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine versus azacitidine alone resulted in CRc of 41% versus 17%, median DoR of 6.5 versus 6.7 months, and median OS of 5.2 versus 4.9 months, respectively.For poor-risk cytogenetics + TP53mut patients, predominant grade ≥3 adverse events (AE) for venetoclax + azacitidine versus azacitidine were febrile neutropenia (55%/39%), thrombocytopenia (28%/28%), neutropenia (26%/17%), anemia (13%/6%), and pneumonia (28%/33%). AEs were comparable between TP53mut and TP53wt patients.

Conclusions: In poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine improved remission rates but not DoR or OS compared with azacitidine alone. However, in poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine resulted in higher remission rates and longer DoR and OS than azacitidine alone, with outcomes comparable with similarly treated patients with intermediate-risk cytogenetics. Toxicities were similar in TP53mut and TP53wt patients. See related commentary by Green and Zeidner, p. 5235.

PubMed Disclaimer

Figures

Figure 1. Study design and molecular classification. Abbreviations: Aza, azacitidine; mut, mutated; Pbo, placebo; wt, wild-type; Ven, venetoclax.
Figure 1.
Study design and molecular classification. Abbreviations: Aza, azacitidine; mut, mutated; Pbo, placebo; wt, wild-type; Ven, venetoclax.
Figure 2. Response rates. A, CR+CRi in patients with poor-risk cytogenetics. B, CR+CRi in patients with intermediate-risk cytogenetics. C, Transfusion independence in patients with poor-risk cytogenetics. D, Transfusion independence in patients with intermediate-risk cytogenetics. E, MRD < 10−3 in patients with poor-risk cytogenetics. F, MRD <10−3 in patients with intermediate-risk cytogenetics. Abbreviations: Aza, azacitidine; CR, complete remission; CRi, CR with incomplete hematologic recovery; mut, mutated; wt, wild-type; Ven, venetoclax.
Figure 2.
Response rates. A, CR+CRi in patients with poor-risk cytogenetics. B, CR+CRi in patients with intermediate-risk cytogenetics. C, Transfusion independence in patients with poor-risk cytogenetics. D, Transfusion independence in patients with intermediate-risk cytogenetics. E, MRD <10−3 in patients with poor-risk cytogenetics. F, MRD <10−3 in patients with intermediate-risk cytogenetics. Abbreviations: Aza, azacitidine; CR, complete remission; CRi, CR with incomplete hematologic recovery; mut, mutated; wt, wild-type; Ven, venetoclax.
Figure 3. Duration of response and OS. A, Duration of response among patients with poor-risk cytogenetics. B, Duration of response among patients with intermediate-risk cytogenetics. C, OS among patients with poor-risk cytogenetics. D, OS among patients with intermediate-risk cytogenetics. Abbreviations: Aza, azacitidine; DoR, duration of response; mut, mutated; wt, wild-type; Ven, venetoclax.
Figure 3.
Duration of response and OS. A, Duration of response among patients with poor-risk cytogenetics. B, Duration of response among patients with intermediate-risk cytogenetics. C, OS among patients with poor-risk cytogenetics. D, OS among patients with intermediate-risk cytogenetics. Abbreviations: Aza, azacitidine; mut, mutated; wt, wild-type; Ven, venetoclax.
Figure 4. Response rates and OS by VAF. A, Response rates by VAF among patients with poor-risk cytogenetics and TP53mut treated with venetoclax + azacitidine. B, OS by variant allelic frequency among patients with poor-risk cytogenetics and TP53mut treated with venetoclax + azacitidine. Abbreviations: CR, complete remission; CRi, CR with incomplete hematologic recovery; NE, not evaluable.
Figure 4.
Response rates and OS by VAF. A, Response rates by VAF among patients with poor-risk cytogenetics and TP53mut treated with venetoclax + azacitidine. B, OS by variant allelic frequency among patients with poor-risk cytogenetics and TP53mut treated with venetoclax + azacitidine. Abbreviations: CR, complete remission; CRi, CR with incomplete hematologic recovery; NE, not evaluable; VAF, variant allele frequency.
See this image and copyright information in PMC

Comment in

References

    1. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. . Age and acute myeloid leukemia. Blood 2006;107:3481–5. - PMC - PubMed
    1. Kim MP, Zhang Y, Lozano G. Mutant p53: multiple mechanisms define biologic activity in cancer. Frontiers Oncol 2015;5:249. - PMC - PubMed
    1. Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, et al. . Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia 2018;32:2546–57. - PMC - PubMed
    1. Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, et al. . TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012;119:2114–21. - PubMed
    1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424–47. - PMC - PubMed

Publication types

MeSH terms

Associated data